Angiotensin-(1-7) and tumors

Abstract

ZHAO Le-Kang, YU Jin-Ming- . Angiotensin-(1-7) and tumors[J]. Journal of International Oncology, 2015, 42(4): 274-276.

［1］ Ferrario CM, Chappell MC, Tallant EA, et al. Counterregulatory actions of angiotensin(17)［J］. Hypertension, 1997, 30(3): 535541. ［2］ Tallant EA, Diz DI, Ferrario CM. Antiproliferative actions of angiotensin(17) in vascular smooth muscle［J］. Hypertension, 1999, 34(2): 950957. ［3］ Santos RA, CampagnoleSantos MJ, Andrade SP. Angiotensin(17): an update［J］. Regul Pept, 2000, 91(13): 4562. ［4］ Welches WR, Santos RA, Chappell MC, et al. Evidence that prolyl endopeptidase participates in the processing of brain angiotensin［J］. J Hypertens, 1991, 9(7): 631638. ［5］ Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase［J］. Life Sci, 1993, 52(18): 14611480. ［6］ Ferrario CM, Iyer SN. Angiotensin(17): a bioactive fragment of the reninangiotensin system［J］. Regul Pept, 1998, 78(13): 1318. ［7］ Rice GI, Thomas DA, Grant PJ, et al. Evaluation of angiotensinconverting enzyme(ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism［J］. Biochem J, 2004, 383(Pt 1): 4551. ［8］ Chappell MC, Pirro NT, Sykes A, et al. Metabolism of angiotensin(17) by angiotensinconvertingenzyme［J］. Hypertension, 1998, 31(2): 362367. ［9］ Iwata M, Cowling RT, Yeo SJ, et al. Targeting the ACE2Ang(17) pathway in cardiac fibroblasts to treat cardiac remodeling and heart failure［J］. J Mol Cell Cardiol, 2011, 51(4): 542547. ［10］ Tikellis C, Bernardi S, Burns WC. Angiotensinconverting enzyme 2 is a key modulator of the reninangiotensin system in cardiovascular and renal disease［J］. Curr Opin Nephrol Hypertens, 2011, 20(1): 6268. ［11］ CastroChaves P, Cerqueira R, Pintalhao M, et al. New pathways of the reninangiotensin system: the role of ACE2 in cardiovascular pathophysiology and therapy［J］. Expert Opin Ther Targets, 2010, 14(5): 485496. ［12］ Giani JF, Mayer MA, Muoz MC, et al. Chronic infusion of angiotensin(17) improves insulin resistance and hypertension induced by a highfructose diet in rats［J］. Am J Physiol Endocrinol Metab, 2009, 296(2): E262E271. ［13］ Liu C, Lv XH, Li HX, et al. Angiotensin(17) suppresses oxidative stress and improves glucose uptake via Mas receptor in adipocytes［J］. Acta Diabetol, 2012, 49(4): 291299. ［14］ Feng Y, Xia H, Cai Y, et al. Brainselective overexpression of human angiotensinconverting enzyme type 2 attenuates neurogenic hypertension［J］. Circ Res, 2010, 106(2): 373382. ［15］ Jiang T, Gao L, Guo J, et al. Suppressing inflammation by inhibiting NFκB pathway contributes to the neuroprotection of angiotensin(17) in rats with permanent cerebral ischemia［J］. Br J Pharmacol, 2012, 167(7): 15201532. ［16］ Leal MC, Pinheiro SV, Ferreira AJ, et al. The role of angiotensin(17) receptor Mas in spermatogenesis in mice and rats［J］. J Anat, 2009, 214(5): 736743. ［17］ Pringle KG, Tadros MA, Callister RJ, et al.The expression and localization of the human placental prorenin/reninangiotensin system throughout pregnancy: roles in trophoblast invasion and angiogenesis?［J］. Placenta, 2011, 32(12): 956962. ［18］ Costa AP, FagundesMoura CR, Pereira VM, et al. Angiotensin(17): a novel peptide in the ovary［J］. Endocrinology, 2003, 144(5):19421948. ［19］ Gallagher PE, Tallant EA. Inhibition of lung cancer cell growth by angiotensin(17)［J］. Carcinogenesis, 2004, 25(11): 20452052. ［20］ Cook KL, MethenyBarlow LJ, Tallant EA, et al. Angiotensin(17) reduces fibrosis in orthotopic breast tumors［J］. Cancer Res, 2010, 70(21): 83198328. ［21］ Krishnan B, Smith TL, Dubey P, et al. Angiotensin(17) attenuates metastatic prostate cancer and reduces osteoclastogenesis［J］. Prostate, 2013, 73(1): 7182. ［22］ SotoPantoja DR, Menon J, Gallagher PE, et al. Angiotensin(17) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor［J］. Mol Cancer Ther, 2009, 8(6): 16761683. ［23］ Menon J, SotoPantoja DR, Callahan MF,et al. Angiotensin(17) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase2［J］. Cancer Res, 2007, 67(6): 28092015. ［24］ Ni L, Feng Y, Wan H, et al. Angiotensin(17) inhibits the migration and invasion of A549 human lung adenocarcinoma cells through inactivation of the PI3K/Akt and MAPK signaling pathways［J］. Oncol Rep, 2012, 27(3):783790. ［25］ Gately S, Li WW. Multiple roles of COX2 in tumor angiogenesis: a target for antiangiogenic therapy［J］. Semin Oncol, 2004, 31(2):211. ［26］ Iniguez MA, Rodriguez A, Volpert OV, et al. Cyclooxygenase2: a therapeutic target in angiogenesis［J］. Trends Mol Med, 2003, 9(2): 7378. ［27］ Martin LJ, Boyd NF. Mammographic density. Potential mechanisms of breast cancer risk associated with mammographic density: hypotheses based on epidemiological evidence［J］. Breast Cancer Res, 2008, 10(1): 201. ［28］ Sheffer Y, Leon O, Pinthus JH, et al. Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapymediated antitumoral effect［J］. Mol Cancer Ther, 2007, 6(2): 570577. ［29］ Kalluri R, Zeisberg M. Fibroblasts in cancer［J］. Nat Rev Cancer, 2006, 6(5): 392401. ［30］ De Wever O, Demetter P, Mareel M, et al. Stromal myofibroblasts are drivers of invasive cancer growth［J］. Int J Cancer, 2008, 123(10): 22292238. ［31］ Guise T. Examining the metastatic niche: targeting the microenvironment［J］. Semin Oncol, 2010, 37 Suppl 2: S214. ［32］ Zhang XH, Wang Q, Gerald W, et al. Latent bone metastasis in breast cancer tied to Srcdependent survival signals［J］. Cancer Cell, 2009, 16(7): 6778. ［33］ Gallagher PE, Tallant EA. Inhibition of human lung cancer cell growth by angiotensin(17)［J］. Carcinogenesis, 2004, 25(11): 20452052.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments